TELESIS BIO (TBIO)
(Real Time Quote from BATS)
$2.42 USD
-0.29 (-10.70%)
Updated Sep 25, 2024 02:26 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Telesis Bio Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 19 | 44 | 83 | 13 | -99,999 |
Receivables | 6 | 6 | 4 | 2 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 4 | 2 | 2 | 1 | NA |
Other Current Assets | 1 | 3 | 4 | 1 | NA |
Total Current Assets | 30 | 55 | 93 | 17 | NA |
Net Property & Equipment | 7 | 7 | 3 | 1 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 5 | 17 | 17 | 6 | NA |
Deposits & Other Assets | 1 | 1 | 1 | 0 | NA |
Total Assets | 70 | 81 | 116 | 27 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 1 | 1 | NA |
Accounts Payable | 3 | 1 | 3 | 1 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 3 | 7 | 5 | 2 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 0 | 4 | 1 | 1 | NA |
Total Current Liabilities | 8 | 14 | 10 | 6 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 5 | 20 | 14 | 3 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 0 | 0 | 2 | NA |
Minority Interest (Liabilities) | 29 | 0 | 0 | 39 | NA |
Total Liabilities | 70 | 35 | 25 | 52 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 162 | 160 | 156 | 1 | NA |
Retained Earnings | -161 | -114 | -65 | -26 | NA |
Other Equity | 0 | 0 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 0 | 47 | 91 | -25 | NA |
Total Liabilities & Shareholder's Equity | 70 | 81 | 116 | 27 | NA |
Total Common Equity | 0 | 47 | 91 | -25 | 0 |
Shares Outstanding | 1.60 | 1.60 | 1.60 | NA | NA |
Book Value Per Share | 0.15 | 29.11 | 56.74 | 0.00 | 0.00 |
Fiscal Year End for Telesis Bio Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 10 | 16 | 19 | 42 | 48 |
Receivables | 1 | 3 | 6 | 5 | 8 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1 | 4 | 4 | 4 | 4 |
Other Current Assets | 2 | 1 | 1 | 1 | 2 |
Total Current Assets | 15 | 23 | 30 | 53 | 62 |
Net Property & Equipment | 4 | 7 | 7 | 7 | 8 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 4 | 5 | 5 | 16 | 17 |
Deposits & Other Assets | 2 | 0 | 1 | 1 | 1 |
Total Assets | 53 | 63 | 70 | 105 | 115 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 15 | 0 |
Accounts Payable | 2 | 2 | 3 | 2 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 3 | 3 | 5 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 0 | 0 | 1 | 3 |
Total Current Liabilities | 8 | 6 | 8 | 25 | 10 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 5 | 5 | 5 | 5 | 20 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 30 | 30 | 29 | 29 | 28 |
Total Liabilities | 73 | 72 | 70 | 87 | 87 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 162 | 162 | 162 | 162 | 161 |
Retained Earnings | -183 | -170 | -161 | -144 | -133 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -21 | -8 | 0 | 18 | 28 |
Total Liabilities & Shareholder's Equity | 53 | 63 | 70 | 105 | 115 |
Total Common Equity | -21 | -8 | 0 | 18 | 28 |
Shares Outstanding | 1.60 | 1.60 | 1.60 | 1.60 | 1.60 |
Book Value Per Share | -12.84 | -5.15 | 0.15 | 11.11 | 17.45 |